Circulating KIM-1 is a minimally invasive biomarker correlated with treatment response to nivolumab in patients with metastatic renal cell carcinoma

BACKGROUND: There are currently no circulating biomarkers used for clinical monitoring of clear cell renal cell carcinoma (ccRCC). Such a biomarker could facilitate individualized treatment decisions and minimize exposure to ineffective therapies. Prior studies have suggested that circulating KIM-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Wenxin, Vemula, Sai V, Niman, Samuel M, Liu, Xiaowen, Takakura, Ayumi, Huang, Zimo, Choueiri, Toni K, Freedman, Matthew L, Catalano, Paul J, Bonventre, Joseph V, Gupta, Saurabh, McDermott, David F, Bhatt, Rupal S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Oral Abstract Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445574/
http://dx.doi.org/10.1093/oncolo/oyad216.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445574/
http://dx.doi.org/10.1093/oncolo/oyad216.004

Ejemplares similares